Cite
HARVARD Citation
Kantarjian, H. et al. (2023). Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results. American journal of hematology. 98 (3), pp. 493-501. [Online].